#USA #Lund #TFS HealthScience #Oncomatryx #OMTX705

TFS HealthScience Deepens Partnership with Oncomatryx for Pancreatic Cancer Drug Trial

In a groundbreaking move to tackle one of the most deadliest cancers, TFS HealthScience has announced an expansion of its collaboration with Oncomatryx. This partnership focuses on a Phase Ib clinical trial for OMTX705, a drug aimed at treating advanced or metastatic pancreatic adenocarcinoma. This innovative product is an antibody-drug conjugate (ADC) specifically designed to target the fibrotic tumor microenvironment, making strides in a field where treatment options are sorely needed.

Collaboration Highlights

The newly initiated trial, set to take place in various medical centers throughout Spain and the United States, aims to evaluate the effectiveness and safety of OMTX705. Previous studies showed promise for this drug, which is designed to inhibit the activator of fibroblasts, thereby potentially leading to better management of pancreatic cancer. The ongoing collaboration between TFS and Oncomatryx build on prior successes, including a Phase I trial that tested OMTX705 as a standalone treatment as well as in conjunction with pembrolizumab in patients with advanced solid tumors.

Current Statistics on Pancreatic Cancer

According to the World Cancer Research Foundation, pancreatic cancer remains a critical public health issue, recording over 510,000 new cases and resulting in more than 466,000 deaths annually. The five-year survival rate is alarmingly low, typically below 10%, indicating an urgent need to explore new therapeutic options. The collaboration between TFS and Oncomatryx reflects a shared commitment to combat these statistics by pioneering treatments that can effectively alter the cancer’s trajectory.

Oncological Expertise

Kris O'Brien, TFS’s VP for Oncology and Rare Diseases, expressed confidence in the collaboration, stating, "Our ongoing partnership reflects a mutual dedication to fast-track the development of innovative therapies for complex cancers like pancreatic adenocarcinoma. TFS leverages its therapeutic expertise and operational agility, helping propel promising scientific discoveries where they are most needed."

Laureano Simón, CEO of Oncomatryx, added, "We are entering an exciting new phase in the clinical development of OMTX705. TFS has proven to be a knowledgeable and trustworthy partner and is key to advancing our science to the patients who urgently require new options."

TFS HealthScience’s Role

With over 20 years of experience, TFS HealthScience brings a wealth of knowledge in oncological research. They have effectively supported clinical trials ranging from early stages to late-stage oncology programs while maintaining an international portfolio that spans 40 countries. Their unique approach, characterized by scientific rigor and adaptability, ensures they remain a vital ally in the ongoing fight against cancer. The renewed collaboration with Oncomatryx reinforces TFS’s mission of delivering tailored clinical solutions that directly contribute to patient lives globally.

Future Directions

Backed by €25 million from a recent funding round, TFS anticipates presenting Phase I clinical data at prominent oncology congresses throughout 2025. The OMTX705 program is rapidly gaining momentum and recognition as a potential new treatment avenue for hard-to-treat cancers, underlining the necessity for continued research and investment in this critical field.

Conclusion

As TFS HealthScience and Oncomatryx prepare to embark on this new clinical trial phase, the hope remains that such collaborations will not only enhance treatment options for pancreatic cancer patients but will also set new standards in oncological research and therapy development. Their efforts exemplify a unified approach to addressing today’s healthcare challenges, illustrating both dedication and innovation in tackling a disease that continues to claim countless lives worldwide.